Sangamo Therapeutics Reports 98.8% Revenue Decline and Financial Challenges

Sangamo Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenues of $581,000, a stark decline of 98.8% compared to $49.4 million in the same quarter of the previous year. For the nine months ending September 30, 2025, revenues totaled $25.3 million, down 50% from $50.2 million in the prior year. This decrease is primarily attributed to the termination of collaboration agreements, particularly with Genentech, which had previously contributed substantial revenue.

Operating expenses for the third quarter of 2025 were $36.1 million, a reduction of 7% from $38.8 million in the same period last year. The decrease in expenses was driven by lower general and administrative costs, which fell by 28% to $8.0 million, while research and development expenses increased slightly by 1% to $28.1 million. For the nine-month period, total operating expenses decreased by 15% to $108.4 million, reflecting ongoing cost management efforts amid declining revenues.

Sangamo's financial position remains precarious, with cash and cash equivalents decreasing to $29.6 million as of September 30, 2025, down from $41.9 million at the end of 2024. The company has expressed substantial doubt about its ability to continue as a going concern, citing the need for significant additional funding to support its operations and research initiatives. The company is actively seeking collaborations and financing options but has faced challenges in securing timely agreements, particularly for its Fabry disease program.

In terms of operational developments, Sangamo has made strides in its neurology-focused initiatives, including the advancement of its investigational therapies for chronic neuropathic pain and prion disease. The company has initiated patient enrollment for its Phase 1/2 STAND study evaluating ST-503, an epigenetic regulator for small fiber neuropathy, and is preparing for a Clinical Trial Application submission for ST-506 targeting prion disease. However, the success of these programs is contingent on securing adequate funding and regulatory approvals.

Looking ahead, Sangamo's management has indicated that the company will need to raise substantial additional capital to continue its operations and advance its product pipeline. The ongoing macroeconomic challenges and the competitive landscape in the biotechnology sector further complicate the company's outlook. The management's ability to execute its strategic plans and secure necessary funding will be critical in determining the future viability of Sangamo Therapeutics.